Skip to main content

Advertisement

SpringerLink
Log in

A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Heading

Abstract

Purpose. The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix.

Methods. PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m2 was given to the first 11 patients and was reduced to 560 mg/m2 for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients.

Results Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia.

Conclusion. PZA at the dose and schedule employed, has insignificant activity in this population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Department of Reproductive Medicine, Medical Center, University of California, San Diego, 402 Dickinson Street, San Diego, CA 92103-8433, USA, , , , ,

    Steven C. Plaxe

  2. Gynecologic Oncology Group, Roswell Park Cancer Institute, Buffalo, NY 14263, USA, , , , ,

    John A. Blessing

  3. Department of Obstetrics and Gynecology, Milton S. Hershey Medical Center/Pennsylvania State University School of Medicine, Hershey, PA 17033, USA, , , , ,

    George Olt

  4. Department of Obstetrics and Gynecology, Division of Oncology, University of Cincinnati, Cincinnati, OH 45267, USA, , , , ,

    Nader Husseinzadah

  5. Department of Obstetrics and Gynecology, Section on Gynecologic Oncology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA, , , , ,

    Samuel S. Lentz

  6. Department of Gynecology Oncology, Rush Medical College, Chicago, IL 60612, USA, , , , ,

    Koen DeGeest

  7. Department of Obstetrics and Gynecology and Reproductive Medicine, State University of New York at Stony Brook, Stony Brook, NY 11794, USA, , , , ,

    Fidel A. Valea

Authors
  1. Steven C. Plaxe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John A. Blessing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George Olt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nader Husseinzadah
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Samuel S. Lentz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Koen DeGeest
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fidel A. Valea
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Electronic Publication

Rights and permissions

Reprints and permissions

About this article

Cite this article

Plaxe, S.C., Blessing, J.A., Olt, G. et al. A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer Chemother Pharmacol 50, 151–154 (2002). https://doi.org/10.1007/s00280-002-0470-2

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-002-0470-2

Search

Navigation